HEALIUS LIMITED — Capital/Financing Update 2021

Sep 21, 2021

ASX Announcement (ASX: HLS)

==> picture [138 x 29] intentionally omitted <==

ASX Limited Market Announcements Office Exchange Centre Level 4, 20 Bridge Street Sydney NSW 2000

HEALIUS LIMITED ACN 064 530 516 REGISTERED OFFICE: LEVEL 6 203 PACIFIC HIGHWAY ST LEONARDS NSW 2065 TEL: +61 2 9432 9400

22 September 2021

Sale of Adora Fertility - update

Healius Limited (Healius) (ASX:HLS) notes the announcement by Virtus Health Limited (ASX:VRT) (Virtus) dated 21 September 2021, concerning the Australian Competition and Consumer Commission’s (ACCC’s) notification of a public review in relation to the sale of the Adora Fertility business. Healius supports Virtus working constructively with the ACCC to achieve a timely outcome.

Healius confirms the position as set out by Virtus in its announcement, that completion of the sale transaction is not conditional on any regulatory approvals. Like Virtus, Healius does not expect the timing of completion previously announced (in Q2 of FY 2022) to change.

ENDS

The release of this Announcement has been authorised by the Disclosure Committee.

For further information contact:

Charlene Jaw Manager, Corporate Affairs Mobile: +61 403 222 810

For over 30 years Healius has been one of Australia’s leading healthcare companies, committed to supporting quality, affordable and accessible healthcare for all Australians. Today, Healius has three businesses, pathology, imaging and day hospitals. Through its unique footprint of centres and its 11,000 employees, Healius provides specialty diagnostic services to consumers and their referring practitioners, as well as enabling independent healthcare professionals to deliver care in its day hospitals.